[4] After the 2007 acquisition of Akyma Pharmaceuticals, a Glasgow, Kentucky-based regional distributor, Amneal launched its own product label.

[10] In December 2019, Amneal announced it had entered into an agreement to acquire a majority interest in AvKARE, a private label provider of generic pharmaceuticals in the US federal agency sector.

The FTC described the merger as having a value of US$1.45 billion, and required the companies to divest several marketed products and development projects as a condition of the approval.

[18] The following is an illustration of the company's major mergers and acquisitions and historical predecessors: As of July 2019, Amneal operated seven Research and Development (R&D) centers in the United States, India and Ireland.

[26] In 2020, in response to the interest in chloroquine and hydroxychloroquine during the COVID-19 pandemic, and before the United States Food and Drug Administration's emergency use authorization was withdrawn, Amneal ramped up production.

[27] In June 2023, the US FDA declined to approve a drug (carbidopa-levodopa) designed to help control symptoms in Parkinson's disease patients for a longer duration, because of inadequate safety data.